Aethlon Medical Stock Price, News & Analysis (NASDAQ:AEMD) $2.19 +0.09 (+4.29%) (As of 09:30 AM ET) Add Compare Share Share Today's Range$2.19▼$2.1950-Day Range$1.42▼$2.2952-Week Range$1.40▼$8.70Volume2,037 shsAverage Volume63,240 shsMarket Capitalization$5.45 millionP/E RatioN/ADividend YieldN/APrice Target$23.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Aethlon Medical MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside995.2% Upside$23.00 Price TargetShort InterestBearish5.25% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($5.34) to ($5.68) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.60 out of 5 stars 3.5 Analyst's Opinion Consensus RatingAethlon Medical has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $23.00, Aethlon Medical has a forecasted upside of 995.2% from its current price of $2.10.Amount of Analyst CoverageAethlon Medical has only been the subject of 1 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.25% of the float of Aethlon Medical has been sold short.Short Interest Ratio / Days to CoverAethlon Medical has a short interest ratio ("days to cover") of 7.9.Change versus previous monthShort interest in Aethlon Medical has recently increased by 26.49%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAethlon Medical does not currently pay a dividend.Dividend GrowthAethlon Medical does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AEMD. Previous Next 1.6 News and Social Media Coverage News SentimentAethlon Medical has a news sentiment score of -0.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.39 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Aethlon Medical this week, compared to 1 article on an average week.MarketBeat Follows1 people have added Aethlon Medical to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aethlon Medical insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.00% of the stock of Aethlon Medical is held by insiders.Percentage Held by InstitutionsOnly 3.02% of the stock of Aethlon Medical is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Aethlon Medical are expected to decrease in the coming year, from ($5.34) to ($5.68) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aethlon Medical is -0.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aethlon Medical is -0.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAethlon Medical has a P/B Ratio of 0.32. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Aethlon Medical Stock (NASDAQ:AEMD)Aethlon Medical, Inc., a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system. The company was founded in 1999 and is based in San Diego, California.Read More AEMD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AEMD Stock News HeadlinesNovember 30, 2023 | americanbankingnews.comAethlon Medical, Inc. (NASDAQ:AEMD) Sees Large Increase in Short InterestNovember 28, 2023 | americanbankingnews.comAethlon Medical (NASDAQ:AEMD) Stock Crosses Below Two Hundred Day Moving Average of $2.82December 6, 2023 | Financial Alphas (Ad)Countries Are Investing Heavily Into Securing Energy IndependenceThere's a worldwide "arms race" for countries to secure lithium - the critical metal essential to powering the world's green energy transition. While the U.S. is now investing heavily into lithium production, the North American supply chain has fallen far behind. One company is on a mission to change that and make a previously remote area the next great lithium mining hub.November 28, 2023 | americanbankingnews.comAethlon Medical (NASDAQ:AEMD) Coverage Initiated at StockNews.comNovember 18, 2023 | markets.businessinsider.comMaxim Group Keeps Their Hold Rating on Aethlon Medical (AEMD)November 16, 2023 | finance.yahoo.comAEMD: Expect Focus on Oncology Studies; Cost Containment EffortsNovember 16, 2023 | finance.yahoo.comAethlon Medical, Inc. (NASDAQ:AEMD) Q2 2024 Earnings Call TranscriptNovember 14, 2023 | finance.yahoo.comAethlon Medical Announces Fiscal Second Quarter Financial Results and Provides Corporate UpdateDecember 6, 2023 | Financial Alphas (Ad)Countries Are Investing Heavily Into Securing Energy IndependenceThere's a worldwide "arms race" for countries to secure lithium - the critical metal essential to powering the world's green energy transition. While the U.S. is now investing heavily into lithium production, the North American supply chain has fallen far behind. One company is on a mission to change that and make a previously remote area the next great lithium mining hub.November 13, 2023 | benzinga.comA Preview Of Aethlon Medical's EarningsNovember 13, 2023 | finance.yahoo.comAethlon Medical Announces Appointment of James B. Frakes, M.B.A. as Interim Chief Executive Officer and Guy Cipriani, M.B.A. as Chief Operating OfficerNovember 11, 2023 | morningstar.comAethlon Medical Inc AEMDNovember 6, 2023 | finance.yahoo.comAethlon Medical to Release Second Quarter Financial Results and Host Conference Call on November 14, 2023November 1, 2023 | msn.comAethlon Medical (AEMD) Price Target Increased by 900.00% to 66.30October 26, 2023 | markets.businessinsider.comPromising Oncology Developments and Positive Outlook Propel Aethlon Medical’s Buy RatingOctober 25, 2023 | msn.comHC Wainwright & Co. Maintains Aethlon Medical (AEMD) Buy RecommendationOctober 12, 2023 | msn.comAethlon Medical receives approval in India for Hemopurifier trialOctober 10, 2023 | finance.yahoo.comAethlon Receives Clearance From Drug Controller General of India For Potential Phase 1 Trial of its Hemopurifier® in OncologyOctober 5, 2023 | finanznachrichten.deAethlon Medical, Inc.: Aethlon Announces Reverse Stock SplitOctober 5, 2023 | seekingalpha.comAethlon Medical to effect 1-for-10 reverse stock split to meet Nasdaq rulesAugust 30, 2023 | finance.yahoo.comAethlon Medical to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceAugust 15, 2023 | markets.businessinsider.comMaxim Group Sticks to Its Hold Rating for Aethlon Medical (AEMD)August 14, 2023 | finance.yahoo.comAEMD: Focusing on Oncology, Infectious Disease & Organ Transplants InitiallyAugust 11, 2023 | finanznachrichten.deAethlon Medical, Inc.: Aethlon Medical Announces Fiscal First Quarter Financial Results and Provides Corporate UpdateAugust 10, 2023 | finance.yahoo.comAethlon Medical Announces Fiscal First Quarter Financial Results and Provides Corporate UpdateAugust 3, 2023 | msn.comAethlon Medical (AEMD) Price Target Decreased by 7.14% to 6.63August 3, 2023 | finance.yahoo.comAethlon Medical to Release First Quarter Financial Results and Host Conference Call on August 10, 2023See More Headlines Receive AEMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aethlon Medical and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/10/2023Today12/06/2023Next Earnings (Estimated)2/12/2024Fiscal Year End3/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AEMD CUSIPN/A CIK773910 Webwww.aethlonmedical.com Phone(858) 459-7800FaxN/AEmployees15Year FoundedN/APrice Target and Rating Average Stock Price Target$23.00 High Stock Price Target$23.00 Low Stock Price Target$23.00 Potential Upside/Downside+995.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($4.82) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-12,030,000.00 Net MarginsN/A Pretax Margin-2,026.66% Return on Equity-83.43% Return on Assets-69.59% Debt Debt-to-Equity RatioN/A Current Ratio6.13 Quick Ratio6.13 Sales & Book Value Annual Sales$570,000.00 Price / Sales9.17 Cash FlowN/A Price / Cash FlowN/A Book Value$6.56 per share Price / Book0.32Miscellaneous Outstanding Shares2,490,000Free Float2,393,000Market Cap$5.23 million OptionableNot Optionable Beta1.46 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. Guy F. Cipriani BS (Eng.) (Age 53)MBA, Chief Operating Officer Comp: $347.5kDr. Steven P. LaRosa M.D. (Age 56)Chief Medical Officer Comp: $430kMr. James B. Frakes M.B.A. (Age 66)Interim CEO, CFO, Senior VP of Finance, Secretary & Director Comp: $385kDr. Lee D. Arnold Ph.D. (Age 63)Chief Scientific Officer Key CompetitorsTenon MedicalNASDAQ:TNONQuoin PharmaceuticalsNASDAQ:QNRXGBSNYSE:GBSGlucoTrackNASDAQ:GCTKAvingerNASDAQ:AVGRView All Competitors AEMD Stock Analysis - Frequently Asked Questions Should I buy or sell Aethlon Medical stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aethlon Medical in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" AEMD shares. View AEMD analyst ratings or view top-rated stocks. What is Aethlon Medical's stock price target for 2024? 1 analysts have issued 1-year price targets for Aethlon Medical's stock. Their AEMD share price targets range from $23.00 to $23.00. On average, they expect the company's share price to reach $23.00 in the next twelve months. This suggests a possible upside of 995.2% from the stock's current price. View analysts price targets for AEMD or view top-rated stocks among Wall Street analysts. How have AEMD shares performed in 2023? Aethlon Medical's stock was trading at $2.7540 at the start of the year. Since then, AEMD stock has decreased by 23.7% and is now trading at $2.10. View the best growth stocks for 2023 here. Are investors shorting Aethlon Medical? Aethlon Medical saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 127,500 shares, an increase of 26.5% from the October 31st total of 100,800 shares. Based on an average trading volume of 16,100 shares, the short-interest ratio is presently 7.9 days. Currently, 5.3% of the shares of the stock are sold short. View Aethlon Medical's Short Interest. When is Aethlon Medical's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, February 12th 2024. View our AEMD earnings forecast. How were Aethlon Medical's earnings last quarter? Aethlon Medical, Inc. (NASDAQ:AEMD) announced its quarterly earnings results on Thursday, August, 10th. The medical equipment provider reported ($1.30) earnings per share for the quarter, missing analysts' consensus estimates of ($1.20) by $0.10. During the same quarter last year, the business earned ($1.90) earnings per share. When did Aethlon Medical's stock split? Aethlon Medical shares reverse split on the morning of Thursday, October 5th 2023. The 1-10 reverse split was announced on Wednesday, October 4th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, October 4th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of Aethlon Medical own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aethlon Medical investors own include Amarin (AMRN), Nokia Oyj (NOK), Vaxart (VXRT), VBI Vaccines (VBIV), Nabriva Therapeutics (NBRV), CRISPR Therapeutics (CRSP), Novavax (NVAX), Organigram (OGI), AT&T (T) and Aurora Cannabis (ACB). Who are Aethlon Medical's major shareholders? Aethlon Medical's stock is owned by many different institutional and retail investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). View institutional ownership trends. How do I buy shares of Aethlon Medical? Shares of AEMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:AEMD) was last updated on 12/6/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aethlon Medical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.